R

RAPT Therapeutics Tech Stack

Clinical-stage immunology biotech developing therapies for inflammatory diseases

Biotechnology Research South San Francisco, California 51–200 employees Founded 2015 Public Company

RAPT Therapeutics is a public clinical-stage biopharmaceutical company focused on immunology-based drug discovery and development. The project pipeline reflects late-stage clinical execution: Phase II/III trials for RPT904, regulatory submission packages, and integrated evidence generation strategies dominate the roadmap. Pain-point data signals operational friction around regulatory compliance, CRO management, and clinical trial complexity — typical challenges for a biotech scaling from preclinical into multi-center studies.

Tech Stack 18 technologies

Core StackActive Directory Intune Okta Slack Zoom DocuSign BambooHR Lattice JAMF Microsoft 365 SharePoint Envoy 1Password Windows macOS Word Excel PowerPoint

What RAPT Therapeutics Is Building

◆Challenges

Downtime reduction
Vulnerability mitigation
Integrated nonclinical safety strategy
Regulatory submission package quality
Cro management compliance
Clinical trial design complexity
Regulatory filing challenges
Patient safety and data integrity
Building medical affairs function
Establishing integrated evidence generation plan

▲Active Projects

Gdpr compliance project
Gxp system validation
Preclinical toxicology and safety pharmacology plans
In vitro adme profiling and translational modeling
Regulatory submission package development
Clinical strategy for rpt904
Phase ii/iii clinical studies
Regulatory filings
Integrated evidence generation plan
Real-world evidence studies

Hiring Activity

Minimal7 roles · 0 in 30d

Department

Research

2

Healthcare

1

HR

1

Operations

1

Ops

1

Seniority

Senior

5

Director

1

Notable leadership hires: Medical Director

Company intelligence

Find more companies like RAPT Therapeutics by tech stack, pain points and active projects

Get started free

About RAPT Therapeutics

RAPT Therapeutics discovers and develops novel therapies targeting inflammatory and immunological diseases, with a focus on modulating immune responses underlying these conditions. Founded in 2015 and publicly traded, the company operates from South San Francisco with 51–200 employees. The organization is research-heavy, with active hiring concentrated in research and healthcare roles at senior and director levels. Current clinical programs include Phase II/III studies and regulatory submission preparation, supported by preclinical work in toxicology, safety pharmacology, and translational ADME modeling.

HeadquartersSouth San Francisco, California

Company Size51–200 employees

Founded2015

Hiring MarketsUnited States

Frequently Asked Questions

What is RAPT Therapeutics working on?

RAPT is advancing Phase II/III clinical studies for RPT904, developing regulatory submission packages, and executing preclinical safety and translational modeling work. The company is also building integrated evidence generation and real-world evidence capabilities to support regulatory filings.

What tech stack does RAPT Therapeutics use?

RAPT's enterprise stack centers on Microsoft 365, Active Directory, Intune, Okta, and Slack for core operations. The company also uses BambooHR and Lattice for workforce management, and DocuSign, Envoy, and 1Password for administrative workflows.